Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Inventiva S.A.

DAIX (FRANCE), NEW YORK (NEW YORK, UNITED STATES), JULY 31, 2025  INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA) (INVENTIVA OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL SMALL MOLECULE THERAPIES FOR THE TREATMENT OF PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), ALSO KNOWN AS NON-ALCOHOLIC STEATOHEPATITIS (NASH), AND OTHER DISEASES WITH SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THE HALF-YEAR REPORT OF ITS LIQUIDITY CONTRACT WITH KEPLER CHEUVREUX.

HALF-YEAR REVIEW OF INVENTIVA'S LIQUIDITY CONTRACT WITH KEPLER CHEUVREUX

DAIX (FRANCE), NEW YORK CITY (NEW YORK, UNITED STATES), JULY 9, 2025  INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA) (INVENTIVA OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED A LEADERSHIP TRANSITION WITH THE APPOINTMENT OF JASON CAMPAGNA, MD, PHD, AS PRESIDENT OF RESEARCH AND DEVELOPMENT (R&D) AND CHIEF MEDICAL OFFICER (CMO) AND MARTINE ZIMMERMANN, PHARMD, AS EXECUTIVE VICE PRESIDENT (EVP) OF REGULATORY AFFAIRS AND QUALITY ASSURANCE.

INVENTIVA NAMES JASON CAMPAGNA AS PRESIDENT OF R&D AND CHIEF MEDICAL OFFICER AND MARTINE ZIMMERMANN AS EXECUTIVE VICE PRESIDENT OF REGULATORY AFFAIRS AND QUALITY ASSURANCE

DAIX (FRANCE), NEW YORK CITY (NEW YORK, UNITED STATES), JULY 7, 2025  INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA) (INVENTIVA OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THE RECEIPT OF A $10 MILLION MILESTONE PAYMENT FROM CHIA TAI-TIANQING PHARMACEUTICAL GROUP CO., LTD (CTTQ), A SUBSIDIARY OF SINO BIOPHARM. THIS MILESTONE PAYMENT FOLLOWS THE SUCCESSFUL SETTLEMENT OF THE SECOND TRANCHE OF 115.6 MILLION1 IN GROSS PROCEEDS (NET PROCEEDS OF 108.5 MILLION) OF THE PREVIOUSLY ANNOUNCED STRUCTURED FINANCING OF UP TO 348 MILLION2 (THE STRUCTURED FINANCING). IN SEPTEMBER 2022, INVENTIVA ENTERED INTO A LICENSING AND COLLABORATION AGREEMENT WITH CTTQ (AS AMENDED ON OCTOBER 11, 2024, THE CTTQ LICENSE AGREEMENT) TO DEVELOP AND COMMERCIALIZE LANIFIBRANOR, INVENTIVA'S PROPRIETARY COMPOUND, FOR THE TREATMENT OF MASH AND POTENTIALLY OTHER METABOLIC DISEASES IN MAINLAND CHINA, HONG KONG SPECIAL ADMINISTRATIVE REGION, MACAU SPECIAL ADMINISTRATIVE REGION AND TAIWAN. UNDER THE CTTQ LICENSE AGREEMENT, INVENTIVA IS ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $265 MILLION OF CLINICAL, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS, AS WELL AS ROYALTIES IN THE LOW SINGLE DIGITS ON ANNUAL NET SALES OF LANIFIBRANOR, IF APPROVED. BASED ON THE RESULTS FROM THE PHASE 2B NATIVE CLINICAL TRIAL, LANIFIBRANOR WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR MASH BY THE U.S. FOOD AND DRUG ADMINISTRATION IN OCTOBER 2020 AND BY THE CHINESE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA) IN DECEMBER 2023. THIS DESIGNATION COULD POTENTIALLY ACCELERATE THE DEVELOPMENT AND REGULATORY REVIEW OF DRUG CANDIDATES FOR SERIOUS OR LIFE-THREATENING CONDITIONS. CTTQ JOINED INVENTIVA'S ONGOING NATIV3 PIVOTAL PHASE 3 CLINICAL TRIAL, WHICH INCLUDES OVER 60 SITES ACROSS MAINLAND CHINA. FURTHERMORE, CTTQ HAS COMPLETED A PHASE I BRIDGING STUDY AND CONFIRMED NO SIGNIFICANT ETHNI

INVENTIVA RECEIVES $10 MILLION MILESTONE PAYMENT FROM CTTQ

DAIX (FRANCE), NEW YORK CITY (NEW YORK, UNITED STATES), JULY 2, 2025  INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA) (INVENTIVA OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCES THE PUBLICATION IN JOURNAL OF HEPATOLOGY REPORTS, A PEER-REVIEWED, SCIENTIFIC JOURNAL, OF RESULTS FROM THE PHASE 2B NATIVE CLINICAL TRIAL AND PRECLINICAL STUDY EVALUATING THE EFFECTS OF LANIFIBRANOR ON LIVER SINUSOIDAL ENDOTHELIAL CELLS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND MASH.

INVENTIVA ANNOUNCES THE PUBLICATION IN JOURNAL OF HEPATOLOGY REPORTS ON RESULTS OF LANIFIBRANOR TREATMENT ON LIVER SINUSOIDAL ENDOTHELIAL CELLS IN PATIENTS WITH MASLD/MASH AND IN PRECLINICAL MODELS OF THE DISEASE

DAIX (FRANCE), NEW YORK CITY (NEW YORK, UNITED STATES), MAY 27, 2025  INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA) (INVENTIVA OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT WILL PARTICIPATE IN TWO UPCOMING INVESTOR CONFERENCES IN JUNE 2025.

INVENTIVA TO PARTICIPATE IN THE UPCOMING JEFFERIES GLOBAL HEALTHCARE CONFERENCE AND UBS SPRING BIOTECH CONFERENCE

DAIX (FRANCE), NEW YORK CITY (NEW YORK, UNITED STATES), MAY 23, 2025  INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA) (THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY REPORTED FINANCIAL INFORMATION FOR THE FIRST QUARTER OF 2025, INCLUDING ITS CASH, CASH EQUIVALENTS AND REVENUES.

INVENTIVA REPORTS 2025 FIRST QUARTER FINANCIAL INFORMATION

DAIX (FRANCE), NEW YORK CITY (NEW YORK, UNITED STATES), MAY 23, 2025 INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA) (THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), TODAY ANNOUNCED THE RESULTS OF THE VOTES OF ITS COMBINED SHAREHOLDERS' MEETING.

RESULTS OF THE VOTES OF THE COMBINED SHAREHOLDERS' GENERAL MEETING OF MAY 22, 2025

DAIX (FRANCE), NEW YORK CITY (NEW YORK, UNITED STATES), MAY 5, 2025  INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA) (INVENTIVA OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL SMALL MOLECULE THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND OTHER DISEASES WITH SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT THE BOARD OF DIRECTORS CALLED THE SECOND TRANCHE OF ITS PREVIOUSLY ANNOUNCED1 STRUCTURED FINANCING OF UP TO 348 MILLION (THE STRUCTURED FINANCING), FOR GROSS PROCEEDS OF 115.6 MILLION (NET PROCEEDS OF 108.5 MILLION) (THE T2 TRANSACTION).

INVENTIVA SECURES THE 116 MILLION SECOND TRANCHE OF ITS STRUCTURED FINANCING OF UP TO 348 MILLION

DAIX (FRANCE), NEW YORK CITY (NEW YORK, UNITED STATES), APRIL 30, 2025  INVENTIVA (EURONEXT PARIS AND NASDAQ: IVA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF ORAL SMALL MOLECULE THERAPIES FOR THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), ALSO KNOWN AS NON-ALCOHOLIC STEATOHEPATITIS (NASH), AND OTHER DISEASES WITH SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THE AVAILABILITY OF THE PREPARATORY DOCUMENTS FOR THE COMBINED GENERAL MEETING OF MAY 22, 2025.

COMBINED GENERAL MEETING OF MAY 22, 2025 - AVAILABILITY OF THE PREPARATORY DOCUMENTS

 BIOMARKER SIGNATURES WERE DEVELOPED TO PREDICT HISTOLOGICAL TREATMENT RESPONSE TO LANIFIBRANOR TREATMENT IN PATIENTS WITH MASH AND FIBROSIS

INVENTIVA ANNOUNCES THE PUBLICATION IN CLINICAL GASTROENTEROLOGY AND HEPATOLOGY OF ITS ANALYSIS OF NEW BIOMARKER SIGNATURES PREDICTIVE OF HISTOLOGICAL RESPONSE IN PATIENTS WITH MASH TREATED WITH LANIFIBRANOR

Inventiva S.A.

IVA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Inventiva S.A.

IVA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IVA